Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a descriptive cohort study within the OpenSAFELY platform
暂无分享,去创建一个
K. Bhaskaran | L. Smeeth | R. Eggo | E. Williamson | A. Walker | S. Bacon | C. Bates | C. Morton | H. Curtis | A. Mehrkar | P. Inglesby | J. Cockburn | H. McDonald | B. MacKenna | L. Tomlinson | I. Douglas | C. Rentsch | R. Mathur | A. Wong | H. Forbes | R. Croker | F. Hester | S. Harper | S. Evans | B. Goldacre | E. Nightingale | W. Hulme | K. Wing | A. Mulick | D. Nitsch | E. Powell | C. Warren-Gash | Anna Schultze | C. Minassian | K. Bhate | D. Evans | S. Davy | G. Hickman | J. Tazare | John Parry | H. Mcdonald | B. Mackenna
[1] Panteleimon G. Takis,et al. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study , 2021, The Lancet.
[2] A. Banerjee,et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study , 2021, BMJ.
[3] K. Bhaskaran,et al. Changes in the rate of cardiometabolic and pulmonary events during the COVID-19 pandemic , 2021, medRxiv.
[4] L. Smeeth,et al. Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study , 2021, The Lancet Digital Health.
[5] C. Catena,et al. Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge , 2021, Clinical Research in Cardiology.
[6] G. Wagener,et al. Mortality and renal outcomes of patients with severe COVID-19 treated in a provisional intensive care unit , 2020, Journal of Critical Care.
[7] Changwei Liu,et al. COVID-19 AND VENOUS DISEASE , 2022 .
[8] D. Gopalan,et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19 , 2020, The Lancet Respiratory Medicine.
[9] S. Nopp,et al. Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis , 2020, Research and Practice in Thrombosis and Haemostasis.
[10] Benjamin S. Glicksberg,et al. AKI in Hospitalized Patients with COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.
[11] M. Landray,et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England , 2020, The Lancet.
[12] K. Bhaskaran,et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.
[13] S. Chakraborty,et al. A Practical Overview and Reporting Strategies for Statistical Analysis of Survival Studies. , 2020, Chest.
[14] Jeffrey J. Goldberger,et al. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors , 2020, Heart Rhythm.
[15] P. Lamendola,et al. COVID-19 and thrombotic complications: Pulmonary thrombosis rather than embolism? , 2020, Thrombosis Research.
[16] D. Klonoff,et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States , 2020, Journal of diabetes science and technology.
[17] Huihui Ren,et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes , 2020, BMJ Open Diabetes Research & Care.
[18] C. Siu,et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review , 2020, Emerging microbes & infections.
[19] F. Meziani,et al. Immunohaemostasis: a new view on haemostasis during sepsis , 2017, Annals of Intensive Care.
[20] Jason P Fine,et al. Practical recommendations for reporting Fine‐Gray model analyses for competing risk data , 2017, Statistics in medicine.
[21] Mei-Jie Zhang,et al. Checking Fine and Gray subdistribution hazards model with cumulative sums of residuals , 2014, Lifetime Data Analysis.
[22] Radford,et al. Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis , 2020 .